HRP20192246T1 - Marker za poremećaje kisele sfingomijelinaze i njegova uporaba - Google Patents
Marker za poremećaje kisele sfingomijelinaze i njegova uporaba Download PDFInfo
- Publication number
- HRP20192246T1 HRP20192246T1 HRP20192246TT HRP20192246T HRP20192246T1 HR P20192246 T1 HRP20192246 T1 HR P20192246T1 HR P20192246T T HRP20192246T T HR P20192246TT HR P20192246 T HRP20192246 T HR P20192246T HR P20192246 T1 HRP20192246 T1 HR P20192246T1
- Authority
- HR
- Croatia
- Prior art keywords
- therapeutic agent
- dose
- use according
- subject
- lyso
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
- C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
- G01N2333/922—Ribonucleases (RNAses); Deoxyribonucleases (DNAses)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
- G01N2405/08—Sphingolipids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361832302P | 2013-06-07 | 2013-06-07 | |
| EP14735056.5A EP3004896B1 (en) | 2013-06-07 | 2014-06-06 | Marker for acid sphingomyelinase disorders and uses thereof |
| PCT/US2014/041405 WO2014197859A1 (en) | 2013-06-07 | 2014-06-06 | Marker for acid sphingomyelinase disorders and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20192246T1 true HRP20192246T1 (hr) | 2020-03-06 |
Family
ID=51062988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20192246TT HRP20192246T1 (hr) | 2013-06-07 | 2014-06-06 | Marker za poremećaje kisele sfingomijelinaze i njegova uporaba |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US10022428B2 (https=) |
| EP (2) | EP3004896B1 (https=) |
| JP (5) | JP6457501B2 (https=) |
| KR (3) | KR102292298B1 (https=) |
| CN (2) | CN105474017A (https=) |
| AU (5) | AU2014274670B2 (https=) |
| CA (1) | CA2914751C (https=) |
| CL (1) | CL2015003563A1 (https=) |
| CR (1) | CR20150638A (https=) |
| DK (1) | DK3004896T3 (https=) |
| EA (1) | EA035342B1 (https=) |
| ES (1) | ES2762608T3 (https=) |
| HR (1) | HRP20192246T1 (https=) |
| HU (1) | HUE047863T2 (https=) |
| IL (3) | IL298675B2 (https=) |
| LT (1) | LT3004896T (https=) |
| MA (1) | MA38638B1 (https=) |
| MX (1) | MX370570B (https=) |
| MY (1) | MY185990A (https=) |
| NZ (1) | NZ754328A (https=) |
| PH (1) | PH12015502687A1 (https=) |
| PL (1) | PL3004896T3 (https=) |
| PT (1) | PT3004896T (https=) |
| RS (1) | RS59677B1 (https=) |
| SG (2) | SG11201509622WA (https=) |
| SI (1) | SI3004896T1 (https=) |
| UA (1) | UA120591C2 (https=) |
| WO (1) | WO2014197859A1 (https=) |
| ZA (1) | ZA201508630B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3998078T1 (sl) * | 2009-08-28 | 2026-02-27 | Genzyme Corporation | Encimsko nadomestno zdravljenje z naraščajočim odmerkom za zdravljenje pomanjkanja kisle sfingomielinaze |
| LT3004896T (lt) * | 2013-06-07 | 2020-01-10 | Genzyme Corporation | Rūgštinės sfingomielinazės sutrikimų žymuo ir jo panaudojimas |
| JP6984854B2 (ja) * | 2015-10-08 | 2021-12-22 | 国立大学法人千葉大学 | ニーマン・ピック病ｃ型を予防または治療するための医薬組成物 |
| KR20250025051A (ko) * | 2017-08-24 | 2025-02-20 | 사노피 | 산성 스핑고미엘린분해효소 결핍증 환자에서의 비정상적 골병태의 치료 |
| AU2018345303B2 (en) | 2017-10-02 | 2025-09-18 | Denali Therapeutics Inc. | Fusion proteins comprising enzyme replacement therapy enzymes |
| EP3976218B1 (en) * | 2019-05-31 | 2025-02-19 | Genzyme Corporation | Two-dimensional lc-ms/ms systems |
| EP4562432A2 (en) * | 2022-07-28 | 2025-06-04 | Wylder Nation Foundation | Compositions and methods for diagnosing, treating, and preventing lysosomal storage diseases |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4082781A (en) | 1976-06-04 | 1978-04-04 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Synthesis of 2-alkanoylamino-4-nitrophenyl phosphorylcholine-hydroxide |
| US4039388A (en) | 1976-06-04 | 1977-08-02 | The United States Of America As Represented By The Government | Diagnostic test for Niemann-Pick disease |
| US5773278A (en) | 1991-05-03 | 1998-06-30 | Mount Sinai Medical Center | Acid sphingomyelinase gene |
| WO2002018539A2 (en) | 2000-08-25 | 2002-03-07 | Lysometrix Corporation | Method for assaying the activity of lysosomal enzymes |
| US7001994B2 (en) | 2001-01-18 | 2006-02-21 | Genzyme Corporation | Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins |
| US7615224B2 (en) | 2004-12-02 | 2009-11-10 | Women's And Children's Hospital | Multiplex-bead complex for determination of lysosomal storage disorders |
| JP2006214731A (ja) | 2005-02-01 | 2006-08-17 | Institute Of Physical & Chemical Research | スフィンゴミエリンの検出方法 |
| JP2009519713A (ja) | 2005-12-15 | 2009-05-21 | ザ リサーチ ファウンデーション オブ ステート ユニバーシティ オブ ニューヨーク | 血漿中及び組織中のスフィンゴエミリン及びホスファチジルコリンの酵素的測定方法 |
| AR059089A1 (es) * | 2006-01-20 | 2008-03-12 | Genzyme Corp | Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal |
| US8026099B2 (en) | 2007-07-26 | 2011-09-27 | Washington University | Lipid profile as a biomarker for early detection of neurological disorders |
| US8497122B2 (en) | 2008-04-11 | 2013-07-30 | Washington University | Biomarkers for Niemann-pick C disease and related disorders |
| SI3998078T1 (sl) * | 2009-08-28 | 2026-02-27 | Genzyme Corporation | Encimsko nadomestno zdravljenje z naraščajočim odmerkom za zdravljenje pomanjkanja kisle sfingomielinaze |
| JP2013002933A (ja) | 2011-06-16 | 2013-01-07 | Hitachi Plant Technologies Ltd | ３次元測位システム |
| CA2854668A1 (en) | 2011-11-15 | 2013-05-23 | Centogene Ag | Method for the diagnosis of niemann-pick disease |
| ES2731920T3 (es) * | 2013-05-14 | 2019-11-19 | Centogene Ag | Método para el diagnóstico de la enfermedad de Niemann-Pick |
| LT3004896T (lt) * | 2013-06-07 | 2020-01-10 | Genzyme Corporation | Rūgštinės sfingomielinazės sutrikimų žymuo ir jo panaudojimas |
-
2014
- 2014-06-06 LT LTEP14735056.5T patent/LT3004896T/lt unknown
- 2014-06-06 WO PCT/US2014/041405 patent/WO2014197859A1/en not_active Ceased
- 2014-06-06 PL PL14735056T patent/PL3004896T3/pl unknown
- 2014-06-06 IL IL298675A patent/IL298675B2/en unknown
- 2014-06-06 NZ NZ754328A patent/NZ754328A/en unknown
- 2014-06-06 HR HRP20192246TT patent/HRP20192246T1/hr unknown
- 2014-06-06 JP JP2016518053A patent/JP6457501B2/ja active Active
- 2014-06-06 CA CA2914751A patent/CA2914751C/en active Active
- 2014-06-06 CN CN201480043918.2A patent/CN105474017A/zh active Pending
- 2014-06-06 US US14/895,472 patent/US10022428B2/en active Active
- 2014-06-06 ES ES14735056T patent/ES2762608T3/es active Active
- 2014-06-06 EP EP14735056.5A patent/EP3004896B1/en active Active
- 2014-06-06 SG SG11201509622WA patent/SG11201509622WA/en unknown
- 2014-06-06 KR KR1020217007269A patent/KR102292298B1/ko active Active
- 2014-06-06 MA MA38638A patent/MA38638B1/fr unknown
- 2014-06-06 HU HUE14735056A patent/HUE047863T2/hu unknown
- 2014-06-06 EA EA201592265A patent/EA035342B1/ru not_active IP Right Cessation
- 2014-06-06 IL IL284102A patent/IL284102B2/en unknown
- 2014-06-06 RS RS20191627A patent/RS59677B1/sr unknown
- 2014-06-06 KR KR1020167000011A patent/KR102228367B1/ko active Active
- 2014-06-06 KR KR1020217025969A patent/KR102434244B1/ko active Active
- 2014-06-06 MY MYPI2015704368A patent/MY185990A/en unknown
- 2014-06-06 DK DK14735056.5T patent/DK3004896T3/da active
- 2014-06-06 SG SG10201709925SA patent/SG10201709925SA/en unknown
- 2014-06-06 EP EP19191053.8A patent/EP3584580A1/en active Pending
- 2014-06-06 AU AU2014274670A patent/AU2014274670B2/en active Active
- 2014-06-06 PT PT147350565T patent/PT3004896T/pt unknown
- 2014-06-06 UA UAA201600158A patent/UA120591C2/uk unknown
- 2014-06-06 MX MX2015016844A patent/MX370570B/es active IP Right Grant
- 2014-06-06 SI SI201431434T patent/SI3004896T1/sl unknown
- 2014-06-06 CN CN202210555370.6A patent/CN115128287A/zh active Pending
-
2015
- 2015-11-23 ZA ZA2015/08630A patent/ZA201508630B/en unknown
- 2015-12-01 PH PH12015502687A patent/PH12015502687A1/en unknown
- 2015-12-04 CR CR20150638A patent/CR20150638A/es unknown
- 2015-12-04 CL CL2015003563A patent/CL2015003563A1/es unknown
- 2015-12-06 IL IL242964A patent/IL242964B/en unknown
-
2018
- 2018-02-09 AU AU2018200977A patent/AU2018200977B2/en active Active
- 2018-06-08 US US16/003,598 patent/US10888607B2/en active Active
- 2018-12-19 JP JP2018236856A patent/JP6835806B2/ja active Active
-
2020
- 2020-10-22 AU AU2020257114A patent/AU2020257114B2/en active Active
- 2020-12-11 US US17/119,035 patent/US11998592B2/en active Active
-
2021
- 2021-02-03 JP JP2021015390A patent/JP7414750B2/ja active Active
-
2023
- 2023-02-23 AU AU2023201062A patent/AU2023201062B2/en active Active
- 2023-12-27 JP JP2023220385A patent/JP7830414B2/ja active Active
-
2024
- 2024-04-29 US US18/649,453 patent/US12589138B2/en active Active
-
2025
- 2025-08-25 AU AU2025220876A patent/AU2025220876A1/en active Pending
- 2025-12-10 JP JP2025244095A patent/JP2026041958A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20192246T1 (hr) | Marker za poremećaje kisele sfingomijelinaze i njegova uporaba | |
| Zegels et al. | Equivalence of a single dose (1200 mg) compared to a three-time a day dose (400 mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study | |
| Giger et al. | Biomedical applications of bisphosphonates | |
| HRP20191957T1 (hr) | Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba | |
| BR112015022896A2 (pt) | drogas de alta penetração e suas composições para o tratamento de doenças de parkinson | |
| SI2903616T1 (en) | The use of masitinib in combination with gemcitabine for the treatment of a subgroup of patients suffering from foot-and-mouth disease | |
| BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
| BR112014004845A2 (pt) | pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
| HRP20251310T1 (hr) | Enzimsko-nadomjesna terapija s povezivanjem doze za liječenje deficita kisele sfingomijelinaze | |
| BR112014004741A2 (pt) | pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
| RU2018108202A (ru) | Способы лечения синдрома леннокса-гасто с использованием фенфлурамина | |
| BR112015001419A2 (pt) | composto, composição farmacêutica, e, métodos para inibir romk em um paciente, para causar diurese, natriurese ou ambos e para tratamento de um ou mais distúrbios | |
| PH12014501620A1 (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| HRP20200117T1 (hr) | Nukleinske kiseline koje se vežu na sdf-1 i njihova upotreba | |
| BR112014028643A8 (pt) | Profármaco de alta penetração, seus usos, e composição farmacêutica | |
| CO6260019A2 (es) | Metodos para el tratamiento de desordenes gastrointestinales independientes de la ingesta de alimento | |
| Reid | Osteoporosis treatment: focus on safety | |
| Muzzi et al. | Anticonvulsant effect of AMP by direct activation of adenosine A1 receptor | |
| HRP20230300T1 (hr) | Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije | |
| HRP20181021T1 (hr) | Formulacija za bispecifične aktivatore limfocita t (bites) | |
| HRP20161147T1 (hr) | Farmaceutski sastav i postupak njegove proizvodnje | |
| EA201591653A1 (ru) | Композиции для лечения глазных расстройств с применением дипиридамола | |
| BR112015012497A8 (pt) | combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial | |
| BR112013024909A2 (pt) | composto, composição farmacêutica, método para o tratamento, prevenção ou melhoria de um ou mais sintomas de desordem, doença, ou condição mediada por pi3k, e método para modular a atividade enzimática de pi3k | |
| WO2009054957A3 (en) | Methods for diagnosis and treatment of chronic fatigue syndrome |